EV/EBITDA Multiple: Crinetics Pharma (CRNX)

Corporate company logo of crinetics.com (CRNX)

The EV/EBITDA valuation multiple on GURU.Markets provides business value data, where the indicator remains at 0.00. Crinetics Pharmaceuticals (CRNX) leverages an academic culture, attracting chemists and biologists through stock option programs. The development of drugs for rare endocrine pathologies is based in US laboratories. Successful trial stages and the hiring of top executives ensure stability and the retention of core competencies.

CRNX (Crinetics Pharmaceuticals, Inc.) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 09/12/2026

crinetics.com (CRNX) - metric breakdowns and financial figures

- market price and analyst price targets:
Price Chart Crinetics Pharma|CRNX - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization Crinetics Corp|CRNX - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Crinetics|CRNX - Total Net Assets|Market Capitalization to Book Value Ratio crinetics.com|CRNX - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Crinetics Pharmaceuticals|CRNX - Long-Term Debt to Equity|Short-Term Debt to Equity Crinetics|CRNX - Company Cumulative Debt|Debt to Book Capitalization Ratio Crinetics Corp|CRNX - Company Long-Term Debt|Company Short-Term Debts Crinetics|Quick Liquidity crinetics.com
- net income and valuation multiples indicators:
CRNX - Net Financial Result|Expected Profit Crinetics Pharmaceuticals|CRNX - Price to Earnings Ratio|Forward P/E Multiple Crinetics Pharmaceuticals|CRNX - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Crinetics Corp|CRNX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Crinetics|CRNX - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months crinetics.com|CRNX - Earnings per share growth this year|Earnings growth forecast for next year Crinetics Pharmaceuticals
- issuer revenue and sales details:
CRNX - Company Total Revenue|Company Future Sales Volume Crinetics Pharma|CRNX - Market Cap to Sales Volume|Forward P/S Multiple Crinetics Corp
Initial company analysis:CRNX (Crinetics Pharma)
Product sample of Crinetics

Crinetics Pharmaceuticals (CRNX) leverages a strategy of outsourcing production and research to minimize capital expenditures while maintaining the flexibility of its scientific center. An analysis of the company's EV/EBITDA ratio allows for an assessment of the total enterprise value, including debt, relative to operating profit, revealing the gap between market expectations and actual capital efficiency, which is critical for determining a fair risk premium.

Who Crinetics Pharmaceuticals competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascendis Pharma Inc. ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA rhythmtx.com|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple NewAmsterdam Pharma Corp|EV/EBITDA Multiple SLNO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FOLD (amicusrx.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 89bio ETNB|Agios (AGIO) - Company Value to EBITDA|GPCR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RZLT: EV/EBITDA Multiple|LXRX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MBX Biosciences|Altimmune Inc (ALT) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aardvark Therapeutics Corp (AARD)|Enterprise Value to EBITDA Ratio Sagimet Biosciences Inc SGMT|EV/EBITDA Multiple BIOA (BioAge Labs, Inc.)|BMEA - Enterprise Value to EBITDA Ratio|QNCX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation GUTS (Fractyl Health Inc.)|VTVT: EV/EBITDA Multiple|ATPC - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pluristem Therapeutics|Enterprise Value to Operating Income Before Depreciation SYBX (Synlogic Corp)|EV/EBITDA Multiple LPCN|MTNB - Company Value to EBITDA|Spruce Biosciences - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio GLTO (Galecto Corporation)|Carmell Corporation - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio lumos-pharma.com LUMO|ONVO: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Radius Recycling Inc.